PERIPHERAL ODONTOGENIC FIBROMA: MIMICKING GINGIVAL SQUAMOUS CELL CARCINOMA: A RARE CASE REPORT AND REVIEW OF LITERATURE

In neoplasms Peripheral Odontogenic Tumors(POT) are one of the rare to occur on gingiva, among them, Peripheral Odontogenic Fibroma (POdF) is the most common. A plethora of lesions sharing similar clinical features, makes the diagnosis difcult. POdF is a benign, slow-growing, smooth, exophytic, painless lesion but it may show diverse clinical presentation as erythematous, lobulated, rapidly growing mass which might be tender on palpation overlapping the features with various inammatory gingival conditions to even a gingival squamous cell carcinoma.This results into diagnostic enigma. Histopathologoical examination plays a vital role in these type of cases. Discussed here is a case of POdF mimicking gingival squamous cell carcinoma. Histopathological investigation showed presence of odontogenic epithelium and dystrophic calcication which are the pathognomonic features of POdF. After surgical removal,POdF is seen to recur but, the exact recurrence rate cannot be estimated due to scarcity of reported cases.

Download Full-text

Slow growing Squamous cell carcinoma over the back masquerading a pigmented naevus clinically – A rare case report

Journal of Dermatology & Dermatologic Surgery ◽

10.1016/j.jdds.2014.03.007 ◽

2015 ◽

Vol 19 (1) ◽

pp. 43-44

Author(s):

Anil Sunkara ◽

R. Venkatesh ◽

V. Srinivasan

Keyword(s):

Squamous Cell Carcinoma ◽

Case Report ◽

Cell Carcinoma ◽

Squamous Cell ◽

Rare Case ◽

Rare Case Report ◽

Slow Growing

Download Full-text

SARCOMATOID SQUAMOUS CELL CARCINOMA OF THE UTERINE CERVIX: A RARE CASE REPORT

10.26226/morressier.5770e29dd462b80290b4c349 ◽

2016 ◽

Author(s):

Diana Moreira

Keyword(s):

Squamous Cell Carcinoma ◽

Case Report ◽

Cell Carcinoma ◽

Squamous Cell ◽

Uterine Cervix ◽

Rare Case ◽

Rare Case Report

Download Full-text

Lentiviral-Mediated Overexpression of MicroRNA-141 Promotes Cell Proliferation and Inhibits Apoptosis in Human Esophageal Squamous Cell Carcinoma

Recent Patents on Anti-Cancer Drug Discovery ◽

10.2174/1574892814666181231142136 ◽

2019 ◽

Vol 14 (2) ◽

pp. 170-176 ◽

Cited By ~ 3

Author(s):

Jun-He Zhang ◽

Hai-Bin Xia

Keyword(s):

Cell Proliferation ◽

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Tumour Growth ◽

Direct Interaction ◽

Vital Role ◽

Expression Level ◽

Luciferase Reporter

Background:Esophageal Carcinoma (EC) is the eighth most common cancer worldwide. Numerous studies have highlighted a vital role of microRNAs (miRNAs) in the development of EC. However, the mechanism of microRNA (miRNA)-141 in Esophageal Squamous Cell Carcinoma (ESCC) remains unknown.Objective:In this study, we explored the effects of miRNA-141 on EC cell proliferation, apoptosis, xenograft tumour growth and their possible mechanisms.Methods :A lentivirus-vector-expressing miRNA-141 was constructed, and a TE-1 cell line of ESCC with a stable expression of miRNA-141 was transfected and screened. The miRNA-141 expression level was detected using qRT-PCR. Effects of miRNA-141 overexpression on cell proliferation and apoptosis were detected using MTT and flow cytometry, respectively. Using a dual-luciferase reporter assay, a direct interaction between miRNA-141 and the 3'-Untranslated Region (UTR) of YAP1 and SOX17 was confirmed. Tumour xenograft experiment in nude mice was used to detect the tumour growth, and the effects of miRNA-141 overexpression on YAP1 and SOX17 were analysed using Western blot.Results:We found that miRNA-141 was highly expressed in TE-1 cells, and miRNA-141 overexpression promoted cell proliferation and inhibited apoptosis. Moreover, the miRNA-141 group showed significantly increased tumour growth ability, luciferase activities and expression levels of YAP1 and SOX17 in the miRNA-141group were significantly down-regulated.Conclusion:miRNA-141 promotes cell proliferation and inhibits apoptosis in ESCC by downregulating the expression level of YAP1 and SOX17, indicating that miRNA-141 may be a potential molecular target for the treatment of ESCC.

Download Full-text

Local Chemotherapy as an Adjuvant Treatment in Unresectable Squamous Cell Carcinoma: What Do We Know So Far?

Current Oncology ◽

10.3390/curroncol28040213 ◽

2021 ◽

Vol 28 (4) ◽

pp. 2317-2325

Author(s):

Luigi Bennardo ◽

Francesco Bennardo ◽

Amerigo Giudice ◽

Maria Passante ◽

Stefano Dastoli ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Gold Standard ◽

Systemic Chemotherapy ◽

Standard Treatment ◽

Case Reports ◽

Case Series ◽

Surgical Removal ◽

Local Chemotherapy

Background: Squamous cell carcinoma (SCC) is one of the most common cancers involving skin and oral mucosa. Although this condition’s gold-standard treatment is the surgical removal of the lesions, the physician must propose alternative treatments in some cases due to the patient’s ineligibility for surgery. Among the available alternative therapies, local chemotherapy may represent an initial treatment in combination with radiotherapy or systemic chemotherapy due to the low frequency of side-effects and the lack of necessity for expensive devices. Methods: In this paper, we review all available literature in various databases (PubMed, Scopus-Embase, Web of Science), proposing local chemotherapy as a treatment for cutaneous and oral SCC. Exclusion criteria included ocular lesions (where topical treatments are common), non-English language, and non-human studies. Results: We included 14 studies in this review. The majority were case reports and case series describing the treatment of non-resectable localized SCC with either imiquimod or 5-fluorouracil. We also analyzed small studies proposing combination treatments. Almost all studies reported an excellent clinical outcome, with a low risk of relapses in time. Conclusions: Resection of the lesion remains the gold-standard treatment for SCC. When this approach is not feasible, local chemotherapy may represent a treatment alternative, and it may also be associated with radiotherapy or systemic chemotherapy.

Download Full-text